AVIR Overview

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Wall Street analysts forecast AVIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVIR is6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Atea Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

Atea Pharmaceuticals Inc. EPS for the last quarter amounts to -0.57 USD, increased 42.50

Atea Pharmaceuticals Inc (AVIR) has 55 emplpoyees as of March 12 2026.

Today AVIR has the market capitalization of 486.00M USD.